Compare ATER & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATER | CLRB |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | 74 | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.0M |
| IPO Year | 2019 | 2008 |
| Metric | ATER | CLRB |
|---|---|---|
| Price | $1.27 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 146.5K | 141.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,975,000.00 | N/A |
| Revenue This Year | $16.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $2.20 |
| 52 Week High | $1.87 | $6.52 |
| Indicator | ATER | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 55.90 |
| Support Level | $0.59 | $2.80 |
| Resistance Level | $1.32 | $3.01 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 30.00 | 69.72 |
Aterian Inc is a consumer products company that operates through online retail channels, including Amazon, Walmart, Target, as well as its own direct-to-consumer websites. The company develops and manages a portfolio of owned brands, which are either internally incubated or acquired, offering products across multiple categories such as home and kitchen appliances, kitchenware, air quality appliances, health and beauty products, and essential oils. Its primary brands include Squatty Potty, HomeLabs, Mueller Living, PurSteam, Healing Solutions, and Photo Paper Direct. The company generates revenue mainly through the online sale of its consumer products, with substantially all sales derived from the Amazon U.S. marketplace.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.